The invention relates to the combination of secnidazole with an antibiotic of the macrolide family, preferably azithromycin 11, for oral treatment of dental infections, which enables a considerable reduction in the length of treatment and the doses administered in comparison with the conventional treatment.

The invention relates to the combination of secnidazole with an antibiotic of the macrolide family preferably azithromycin 11 for oral treatment of dental infections which enables a considerable reduction in the length of treatment and the doses administered in comparison with the conventional treatment.

FIELD: medicine.SUBSTANCE: method involves simulating gestosis in Wistar rats by the daily intraperitoneal introduction of L-nitro-arginine-methyl ester 25 mg/kg for 7 days. That is followed by the intragastric introduction of azithromycin 30 mg/kg once a day in the setting of the model above from 14to 20day of pregnancy.EFFECT: method provides the manifested endothelial dysfunction correction in the special pathogenesis environment in the pregnant females in a combination with eliminating acute...

FIELD: medicine.SUBSTANCE: azithromycin infusions are combined with the daily administration of metronidazole. Azithromycin is administered in a single dose of 1.0 g on the 5th post-infusion day. The treatment is combined with the daily administration from the first day of the metronidazole therapy twice a day in a dose of 500 mg for 14 days.EFFECT: effective treatment ensured by reducing a dose and risk of side effects.3 ex

The invention relates to an amorphous non-crystalline glass form (2R3S4R5R8R10R11R12S13S14R)-2-ethyl-3410-trihydroxy-3568101214-heptamethyl-15-oxo-11-{[346-trideoxy-3-(dimethylamino)-&bgr;-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadec-13-yl 26-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranoside or azithromycin having an infra-red pattern displaying characteristic relatively broad peaks at approximately 3500 and 1727 cm−1 and characteristic peaks at approximately 2970 and 2938 ...